Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide Vial - Available for research purposes
Retatrutide is an experimental, once-daily injectable peptide drug designed to promote weight loss by activating multiple hormone receptors involved in appetite and metabolism. As a triple agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide aims to reduce food intake, increase energy expenditure, and improve glucose control. Early clinical trials have shown substantial average reductions in body weight in adults with obesity, along with improvements in metabolic markers such as fasting glucose and lipid profiles. Commonly reported side effects mirror those of other incretin-based therapies and include gastrointestinal symptoms (nausea, vomiting, diarrhea) and potential transient increases in heart rate. Retatrutide remains under clinical investigation; safety, optimal dosing, and long-term effects are still being evaluated.
Retatrutide Vial - Available for research purposes
Retatrutide is an experimental, once-daily injectable peptide drug designed to promote weight loss by activating multiple hormone receptors involved in appetite and metabolism. As a triple agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide aims to reduce food intake, increase energy expenditure, and improve glucose control. Early clinical trials have shown substantial average reductions in body weight in adults with obesity, along with improvements in metabolic markers such as fasting glucose and lipid profiles. Commonly reported side effects mirror those of other incretin-based therapies and include gastrointestinal symptoms (nausea, vomiting, diarrhea) and potential transient increases in heart rate. Retatrutide remains under clinical investigation; safety, optimal dosing, and long-term effects are still being evaluated.